HIV DIAGNOSIS AND TREATMENT MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: BYR-180385 |   Healthcare

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

HIV Diagnosis and Treatment Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL HIV DIAGNOSIS AND TREATMENT MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL HIV DIAGNOSIS AND TREATMENT MARKET

7.1 GLOBAL HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA HIV DIAGNOSIS AND TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 Viiv Healthcare Group of Companies, Inc.

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Boehringer Ingelheim Gmbh

16.3 Bristol-Myers Squibb Company

16.4 Cipla Inc.

16.5 F. Hoffmann-La Roche Ltd

16.6 Gilead

16.7 Glaxosmithkline Plc.

16.8 Hologic Inc.

16.9 Viiv Healthcare Group of Companies, Inc.

16.10 Janssen Diagnostics

16.11 Johnson & Johnson Services

16.12 Merck & Co. Inc.

16.13 Mylan Inc.

16.14 Qiagen

16.15 Roche Diagnostics

16.16 Siemens Healthcare

16.17 Sysmex Corporation

16.18 Zyomyx Inc.

16.19 Partec

16.20 Pointcare Technologies Inc.

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

By Test Type
Antibody Tests
   Hiv-1 Screening Tests
   Hiv-1 Antibody Confirmatory Tests
   Hiv-2 & Group O Diagnostic Tests
Viral Identification Assays
Cd4 Testing
Viral Load Testing
Early Infant Diagnostics
By Diagnostic Product
Assays, Kits & Reagents
Instruments
Software & Service
Others (Poc and Single Blood Drop Analyser)
By Treatment
Protease Inhibitors (Pis)
Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis)
Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (Nrtis)
Entry or Fusion Inhibitors
Integrase Inhibitors
Others
By End User
Diagnostic Laboratories
Hospitals
Blood Banks
Home Care Settings
Other End Users

Companies

Viiv Healthcare Group of Companies, Inc.
Boehringer Ingelheim Gmbh
Bristol-Myers Squibb Company
Cipla Inc.
F. Hoffmann-La Roche Ltd
Gilead
Glaxosmithkline Plc.
Hologic Inc.
Viiv Healthcare Group of Companies, Inc.
Janssen Diagnostics
Johnson & Johnson Services
Merck & Co. Inc.
Mylan Inc.
Qiagen
Roche Diagnostics
Siemens Healthcare
Sysmex Corporation
Zyomyx Inc.
Partec
Pointcare Technologies Inc.

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.